IL5 and asthma: The use of biologics in asthma, includes the IgE-targeted antibody omalizumab, the IL‐5-targeted antibody mepolizumab, the IL -13-targeted antibody tralokinumab, the IL- 9-targeted monoclonal antibody MEDI-528 and TNFα-blocking antibodies such as infliximab, golimumab and soluble TNFα receptor fusion proteins [58].